Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas

被引：0

作者：

Frakulli, Rezarta ^{[1
]}

Salvi, Fabrizio ^{[2
]}

Balestrini, Damiano ^{[2
]}

Parisi, Alessandro ^{[2
]}

Palombarini, Marcella ^{[3
]}

Cammelli, Silvia ^{[1
]}

Rocca, Michele ^{[4
]}

Salone, Mariacristina ^{[4
]}

Longhi, Alessandra ^{[5
]}

Ferrari, Stefano ^{[5
]}

Morganti, Alessio G. ^{[1
]}

Frezza, Giovanni ^{[2
]}

机构：

[1] Univ Bologna, Dept Expt Diagnost & Specialty Med, Radiat Oncol Ctr, I-40138 Bologna, Italy

[2] Bellaria Hosp, Radiat Oncol Unit, Bologna, Italy

[3] Bellaria Hosp, Med Phys Unit, Bologna, Italy

[4] Rizzoli Orthopaed Inst, Gen & Thorac Surg, Bologna, Italy

[5] Rizzoli Orthopaed Inst, Dept Oncol, Bologna, Italy

来源：

ANTICANCER RESEARCH | 2015年 / 35卷 / 10期

关键词：

SBRT; sarcoma; lung metastases; PULMONARY METASTASES; SBRT;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The purpose of this study was to evaluate local control and toxicity in a group of patients treated with stereotactic body radiotherapy (SBRT) for lung metastases (LM) from bone and soft tissue sarcomas. Patients and Methods: From October 2010 to July 2014, patients with LM from sarcomas not suitable for surgery were treated with daily cone-beam computed tomography-guided SBRT. The dose administered ranged from 30 to 60 Gy in 3-8 fractions. Acute and late toxicity were scored according to Common Terminology Criteria for Adverse Events version 4.0. Results: A total of 24 patients with 68 LM from sarcomas were treated with SBRT. The median follow-up after SBRT was 17 months (range=11-51 months). Two-year actuarial lesion local control and overall survival were 85.9% and 66.4%, respectively. No G3 or greater acute and late toxicities were observed. Conclusion: SBRT is a safe and effective treatment for LM from sarcoma and might be used as an alternative option in patients unfit for surgery.

引用

页码：5581 / 5586

页数：6

共 50 条

[41] A review: molecular aberrations within Hippo signaling in bone and soft-tissue sarcomas
Deel, Michael D.
Li, Jenny J.
Crose, Lisa E. S.
Linardic, Corinne M.
FRONTIERS IN ONCOLOGY, 2015, 5
[42] Prognostic factors of retroperitoneal soft-tissue sarcomas
Derici, Hayrullah
Tansug, Tugrul
Nazli, Okay
Bozdag, Ali Dogan
Reyhan, Enver
Kara, Cemal
CHIRURGISCHE GASTROENTEROLOGIE, 2006, 22 (03): : 179 - 184
[43] SPECIAL PROBLEMS OF GASTROINTESTINAL SOFT-TISSUE SARCOMAS
LEHNERT, T
CHIRURG, 1993, 64 (07): : 535 - 543
[44] Newer therapeutic strategies for soft-tissue sarcomas
Bourcier, Kevin
Italiano, Antoine
PHARMACOLOGY & THERAPEUTICS, 2018, 188 : 118 - 123
[45] SOFT-TISSUE SARCOMAS THAT MIMIC BENIGN LESIONS
HOLLOWOOD, K
FLETCHER, CDM
SEMINARS IN DIAGNOSTIC PATHOLOGY, 1995, 12 (01) : 87 - 97
[46] Prognostic factors in stereotactic body radiotherapy of lung metastases
Borm, K. J.
Oechsner, M.
Schiller, K.
Peeken, J. C.
Dapper, H.
Munch, S.
Kroll, L.
Combs, S. E.
Duma, M. N.
STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (10) : 886 - 893
[47] Imaging Soft-tissue Sarcomas of the Head and Neck: A Tertiary Soft-tissue Sarcoma Unit Experience
Jaly, Alaa Alsadik
Thway, Khin
Touska, Philip
Wale, Anita
Miah, Aisha
Kerawala, Cyrus
Riva, Francesco
Moskovic, Eleanor
Jones, Robin L.
Strauss, Dirk
Dafydd, Derfel A. P.
Messiou, Christina
ANTICANCER RESEARCH, 2019, 39 (11) : 6223 - 6230
[48] Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas
Christie-Large, M.
James, S. L. J.
Tiessen, L.
Davies, A. M.
Grimer, R. J.
EUROPEAN JOURNAL OF CANCER, 2008, 44 (13) : 1841 - 1845
[49] SOFT-TISSUE SARCOMAS OF THE SHOULDER GIRDLE - FACTORS INFLUENCING LOCAL RECURRENCE, DISTANT METASTASES, AND SURVIVAL
METERISSIAN, SH
REILLY, JA
MURPHY, A
ROMSDAHL, MM
POLLOCK, RE
ANNALS OF SURGICAL ONCOLOGY, 1995, 2 (06) : 530 - 536
[50] Grading of soft tissue and bone sarcomas
Petersen, I.
Wardelmann, E.
PATHOLOGE, 2016, 37 (04): : 320 - 327

← 1 2 3 4 5 →